Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

294 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Aggressive Lymphoma after CD19 CAR T-Cell Therapy.
Kobbe G, Brüggemann M, Baermann BN, Wiegand L, Trautmann H, Yousefian S, Libertini S, Menssen HD, Maier HJ, Ulrich P, Gao J, Bruch PM, Liebers N, Radujkovic A, Seifert M, Schniederjohann C, Paramasivam N, Fitzgerald D, Seidel M, Esposito I, Germing U, Cadeddu RP, Nachtkamp K, Jäger P, Ulrych T, Fischer JC, Rox JM, Giesel F, Koch R, Antoch G, Distler JHW, Meuth SG, Jacobsen M, Hübschmann D, Lu J, Iaccarino I, Haas S, Damm F, Dietrich S. Kobbe G, et al. Among authors: bruggemann m. N Engl J Med. 2024 Oct 3;391(13):1217-1226. doi: 10.1056/NEJMoa2402730. N Engl J Med. 2024. PMID: 39589371
Pathology in the legal framework of European and German medical device law: Operation, use and in-house manufacture of in vitro diagnostic medical devices.
Kahles A, Goldschmid H, Volckmar AL, Kazdal D, Gassner UM, Vogeser M, Brüggemann M, Bürrig KF, Kääb-Sanyal V, Flechtenmacher C, Schirmacher P, Stenzinger A. Kahles A, et al. Among authors: bruggemann m. Ger Med Sci. 2024 Oct 11;22:Doc09. doi: 10.3205/000335. eCollection 2024. Ger Med Sci. 2024. PMID: 39559338 Free PMC article. Review.
Next-generation sequencing and high DNA input identify previously missed measurable residual disease in peripheral blood of B-cell precursor acute lymphoblastic leukaemia.
Bendig S, Bufe S, Kotrova M, Fricke B, Proske C, Darzentas F, Darzentas N, Schilhabel A, Kehden B, Chitadze G, Baldus CD, Gökbuget N, Brüggemann M. Bendig S, et al. Among authors: bruggemann m. Br J Haematol. 2024 Oct 24. doi: 10.1111/bjh.19834. Online ahead of print. Br J Haematol. 2024. PMID: 39449173 No abstract available.
Long-read transcriptome sequencing of CLL and MDS patients uncovers molecular effects of SF3B1 mutations.
Pacholewska A, Lienhard M, Brüggemann M, Hänel H, Bilalli L, Königs A, Heß F, Becker K, Köhrer K, Kaiser J, Gohlke H, Gattermann N, Hallek M, Herling CD, König J, Grimm C, Herwig R, Zarnack K, Schweiger MR. Pacholewska A, et al. Among authors: bruggemann m. Genome Res. 2024 Nov 20;34(11):1832-1848. doi: 10.1101/gr.279327.124. Genome Res. 2024. PMID: 39271291 Free PMC article.
Third-generation anti-CD19 CAR T cells for relapsed/refractory chronic lymphocytic leukemia: a phase 1/2 study.
Derigs P, Schubert ML, Dreger P, Schmitt A, Yousefian S, Haas S, Röthemeier C, Neuber B, Hückelhoven-Krauss A, Brüggemann M, Bernhard H, Kobbe G, Lindemann A, Rummel M, Michels B, Korell F, Ho AD, Müller-Tidow C, Schmitt M. Derigs P, et al. Among authors: bruggemann m. Leukemia. 2024 Nov;38(11):2419-2428. doi: 10.1038/s41375-024-02392-7. Epub 2024 Aug 27. Leukemia. 2024. PMID: 39192036 Free PMC article. Clinical Trial.
Advancing evolutionary medicine in Northern Germany: Collaboration between Kiel University's Medical Faculty and the Max Planck Institute for Evolutionary Biology.
Baines JF, Baldus CD, Bertels F, Brüggemann M, Kaleta C, Laudes M, Mueller FJ, Odenthal-Hesse L, Poyet M, Rainey PB, Rosenstiel P, Scheffold A, Sebens S, Thiery J, Traulsen A. Baines JF, et al. Among authors: bruggemann m. Evol Med Public Health. 2024 Jul 24;12(1):117-121. doi: 10.1093/emph/eoae013. eCollection 2024. Evol Med Public Health. 2024. PMID: 39114444 Free PMC article. No abstract available.
First-line venetoclax combinations versus chemoimmunotherapy in fit patients with chronic lymphocytic leukaemia (GAIA/CLL13): 4-year follow-up from a multicentre, open-label, randomised, phase 3 trial.
Fürstenau M, Kater AP, Robrecht S, von Tresckow J, Zhang C, Gregor M, Thornton P, Staber PB, Tadmor T, Lindström V, Juliusson G, Janssens A, Levin MD, da Cunha-Bang C, Schneider C, Goldschmidt N, Vandenberghe E, Rossi D, Benz R, Nösslinger T, Heintel D, Poulsen CB, Christiansen I, Frederiksen H, Enggaard L, Posthuma EFM, Issa DE, Visser HPJ, Bellido M, Kutsch N, Dürig J, Stehle A, Vöhringer M, Böttcher S, Schulte C, Simon F, Fink AM, Fischer K, Holmes EE, Kreuzer KA, Ritgen M, Brüggemann M, Tausch E, Stilgenbauer S, Hallek M, Niemann CU, Eichhorst B. Fürstenau M, et al. Among authors: bruggemann m. Lancet Oncol. 2024 Jun;25(6):744-759. doi: 10.1016/S1470-2045(24)00196-7. Lancet Oncol. 2024. PMID: 38821083 Free article. Clinical Trial.
294 results